Hyperlipidemia and Erectile Dysfunction

Yıl 2018, Cilt: 13 Sayı: 3, 91 - 96, 15.11.2018

Dilek Tüzün

https://doi.org/10.17517/ksutfd.393397

Cited By: 1

Öz

Normal erectile function requires the presence of many regulatory systems and coordination, as well as the interaction of physiological, hormonal, neurological, vascular, and the cavernous factor. Alterations in any of these factors is enough on the occurrence of erectile dysfunction, but in many cases, changes of these factors is present in combined form. Increase  in vascular risk factors such as hyperlipidemia, smoking, hypertension, heart disease, family history, lifestyle, obesity and diabetes, increases the incidence of erectile dysfunction.

Anahtar Kelimeler

Erectile dysfunction, hyperlipidemia, Phosphodiesterase 5 inhibitor

Hiperlipidemi ve Erektil Disfonksiyon

Öz

Normal erektil fonksiyon, bircok düzenleyici sistemin
varlığı ve koordinasyonunu, ayrıca fizyolojik, hormonal, nörolojik, vasküler ve
kavernozal faktörlerin etkileşimini gerektirir. Bu faktörlerin herhangi birinde
oluşan değişiklik, erektil disfonksiyonun oluşması icin yeterli olmakla
beraber; bircok vakada bu etkenlerin değişiklikleri kombine şekilde
bulunmaktadır. Hiperlipidemi, sigara kullanımı, hipertansiyon, kalp hastalığı,
aile hikayesi, hayat tarzı, obezite ve diyabet gibi damarsal risk faktörleri arttıkca,  erektil disfonksiyon görülme olasılığı da
artmaktadır.

Anahtar Kelimeler

Erektil disfonksiyon, hiperlipidemi, Fosfodiesteraz 5 inhibitörü

Kaynakça

• 1-NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.; JAMA. 1993; 7;270(1):83-90.
• 2- Lewis R, Hatzichristou D, Laumann E, McKinlay J. Epidemiology and natural history of erectile dysfunction; risk factors including iatrogenic and aging. In: Jardin A,Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R (eds). Erectile Dysfunction. First International Consultation on Erectile Dysfunction. Health Publications, Ltd.: Plymouth, 2000, pp 21–52.
• 3-Lue TF. Erectile dysfunction.; N Engl J Med. 2000;15;342(24):1802-1813.
• 4- Tuncel A, Özer G, Atan A. Erektil disfonksiyonda rol oynayan risk faktörlerini belirleme. Androloji Bülteni. 2013; 54:158-163.
• 5-Anafarta K, Penil ereksiyon ve empotans. Ozdiler E, Aydos K (eds): Klinik Androloji Ankara Universitesi Basımevi, 2000, 337-377, Ankara
• .6- Lue TF. Erectile dysfunction.; N Engl J Med. 2000; 342(24):1802-1813.
• 7-Andersson KE, Wagner G. Physiology of penile erection.; Physiol Rev.1995 ;75(1):191-236.
• 8-Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004;170(9):1429-1437.
• 9- Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460–463.
• 10- Broderick GA. Intracavernous pharmacotherapy. Treatment for the aging erectile response. Urol Clin N Am 1995; 23: 111–126.
• 11- Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004;171:2341–5.
• 12- Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/ epidemiology/risk factors for sexual dysfunction.; J Sex Med. 2010;7:1598-1607.
• 13- Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1991;146:238–40.
• 14- Sullivan ME, Dashwood MR, Thompson CS, Mikhailidis DP, Morgan RJ. Down-regulation of endothelin-B receptor sites in cavernosal tissue of hypercholesterolaemic rabbits. Br J Urol 1998;81: 128–34.
• 15- Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994;46:137–42.
• 16-Sullivan ME, Keoghane SR, Miller MAW. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87: 838–845.
• 17- Tanner FC, Noll G, Boulanger CM, Lüscher TF. Oxidised low density lipoproteins inhibit relaxations of porcine coronary arteries. Circulation 1991; 83: 2012–2020.
• 18- Rosenfeld ME. Oxidised LDL affects multiple atherogenic cellular responses. Circulation 1991; 83: 2137–2140.
• 19- Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160–162.
• 20-Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496–1500.
• 21- Juenemann KP, Muth S, Rohr G, et al.Does lipid metabolism influence the pathogenesis of vascular impotence? Int J Impot Res 1990; 2(Suppl 2): 33.
• 22- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
• 23- Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151–7.
• 24- Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational men’s attitudes to life events and sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607–17.
• 25- Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140:930–7.
• 26-Atahan O, Kayigil O, Hizel N, Metin A. Is apolipoprotein-(a) an important indicator of vasculogenic erectile dysfunction? Int Urol Nephrol 1998; 30:185–91.
• 27- Nikoobakht M, Nasseh H, Pourkasmaee M. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005;17:523–6.
• 28- El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005; 96:1079–86.
• 29- Sullivan ME, Miller MA, Bell CR, et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int Angiol 2001;20:195–9.
• 30- Bodie J, Lewis J, Schow D, Monga M. Laboratory evaluations of erectile dysfunction: An evidence based approach. J Urol 2003;169:2262–4.
• 31-Roumeguere T,Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44:355–9.
• 32-Kendirci M, Nowfar S, Hellstrom WJ. The impact of vascular risk factors on erectile function. Drugs Today (Barc) 2005;41:65–74.
• 33-Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002;5:19–24.
• 34- Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician’s knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: A National Research Network (NRN) survey. J Am Board Fam Med 2006;19:46–53.
• 35- Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54–9.
• 36- Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255–258.
• 37- Kim JH, Klyachkin ML, Svendsen E, et al. Experimental hypercholesterolaemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994; 151: 198–205.
• 38- Manning M, Schmidt P, Juenemann KP, Alken P. The role of blood lipids in erectile failure. Int J Impotence Res 1996; 8: 167 (D179).
• 39-Kim SC. Hyperlipidemia and erectile dysfunction. Asian J Androl 2000; 2: 161–166.
• 40-Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in the community: a prevalence study. Med J Aust 1999; 171: 353–357.
• 41- Junemann K, Aufenanger J, Konrad T, et al. The effect of impaired lipid metabolism on the smooth muscle cells of rabbits. Urol Res 1991;19:271–5.
• 42- Wespes E, Moreira de Goes P, Schulman C. Vascular impotence:focal or diffuse penile disease? J Urol 1992;148:1435–6.
• 43-Theuma P, Fonseca VA. Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes. Curr Drug Targets 2003; 4: 477–86.
• 44-Chan NN, Chan JC: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609– 16.
• 45-Nash DT: Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 2002; 287: 1451– 2.
• 46-Yücetürk CN, Özgür BC. Metabolik sendrom ile erektil disfonksiyon ilişkisi. Yeni Üroloji Dergisi 2013; 8 (2): 79-86.
• 47-Masuda H, Tsujii T, Okuno T, et al. Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002; 282: 1730– 8.
• 48- Eaton CB. Hyperlipidemia. Prim Care 2005;32: 1027–55.
• 49-Billups KL, Kaiser DR, Kelly AS, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003;15:231–6.
• 50-Aoki R, Ikarugi H, Naemura A, Ijiri Y, Yamashita T, Yamamoto J. Endothelial dysfunction precedes atherosclerotic lesions and platelet activation in high fat diet-induced prothrombotic state. Thromb Res 2006;117:529–35.
• 51-Baumhakel M, Bohm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract 2007;61:361–6.
• 52- Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: History and impact on cardiovascular disease. Vascul Pharmacol 2006;45:268–76.
• 53- Bank AJ, Kelly AS, Kaiser DR, et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006;11:251–7.
• 54- Hong SK, Han BK, Jeong SJ, Byun SS, Lee SE. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J Urol 2007;178:613–6.
• 55- Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996;21:89–94.
• 56- Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141–5.
• 57- Davis R, Reveles KR, Ali SK, Mortensen EM, Frei CR, Mansi I. Statins and male sexual health: a retrospective cohort analysis. J Sex Med. 2015;12:158-67.
• 58- Iakovenko EI, Evdakimova AA, Toguzova ZA, Sharvadze GG, Mamedov MN. Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk]. Kardiologiia. 2014;54(2):37-42.
• 59- Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014;11(7):1626-35.
• 60- Nurkalem Z, Yildirimtürk Ö, Özcan KS, Kul Ş, Çanga Y, Satılmış S, BozbeyoğluE, Kaya C. The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients. Kardiol Pol. 2014;72(3):275-9.
• 61- Fink HA, Mac DR, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349– 60.
• 62-American Urological Association. Management of erectile dysfunction. American Urological Association (AUA) Education and Research, Inc. 2005. Available at: http://www.auanet.org (accessed August 7, 2007).
• 63- DeSouza C, Parulkar A, Lumpkin D, et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336–9
• .64-Lewis RW, Sadovsky R, Eardley I, et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517–31.
• 65- Miner M, Billups KL. Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins. J Sex Med 2008;5:1066–1078.